Baxfendy was approved in the US for hypertension in adults not adequately controlled on other antihypertensive medicines. The approval was based on Phase III BaxHTN results showing significant systolic blood pressure reductions.
Finerenone met its primary endpoint in reducing albuminuria in type 1 diabetic kidney disease, marking the first successful drug trial in 30 years for this population. Separately, SGLT2 inhibitors showed superior kidney protection compared to GLP-1 medications in type 2 diabetes patients.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07772856 |
Liberalizing Potassium Restrictions in Patients Receiving Hemodialysis |
NOT_YET_RECRUITING | NA |
| NCT07494266 |
Safety of a Healthy Plant-based Diet With Higher Potassium Content, Compared to a Healthy Plant-based Diet With Limited Potassium Content in Patients With Chronic Kidney Disease: A Pilot Study |
NOT_YET_RECRUITING | NA |
| NCT07370194 |
Observational Study on the Prevalence and Risk Factors of Patients With Hyperkalaemia in Brazil |
RECRUITING | |
| NCT06884267 |
Hyperkalemia Quality Improvement Program (HK-QIP) Study |
ACTIVE_NOT_RECRUITING | NA |
| NCT05766839 |
Patiromer for Treatment of Hyperkalaemia in Children Under 12 Years of Age |
RECRUITING | PHASE2 |
| NCT03253172 |
Potassium Supplementation in CKD |
ACTIVE_NOT_RECRUITING | NA |
